Events
Catch a glimpse of our latest gatherings, milestones and noteworthy moments.
21st Annual WORLDSymposium
WORLDSymposium is designed for basic, translational and clinical researchers, patient advocacy groups, clinicians, and all others who are interested in learning more about the latest discoveries related to lysosomal diseases and the clinical investigation of these advances. Each year, WORLDSymposium presents the latest information from basic science, translational research, and clinical trials for lysosomal diseases.
ASENT 2025
Join us as the American Society for Experimental Neurotherapeutics Annual Meeting (ASENT 2025) will be held at Hyatt Regency Bethesda, in Bethesda, MD from March 12-14, 2025.
SOT 64th Annual Meeting and ToxExpo
The SOT 64th Annual Meeting and ToxExpo will feature five days of Featured and Scientific Sessions, poster presentations, and social events, as well as the popular three-day ToxExpo.
United States Biopharma Workforce Partnership Conference
Mark your calendars for the 2025 U.S. Biopharma Workforce Partnership Conference on March 26-27, 2025, at the Durham Convention Center in Durham, North Carolina. Focused on partnership formation and best practice sharing, the conference is a must for industry, academic, and nonprofit professionals focused on educating, training, recruiting, and growing talent in the biopharmaceutical industry.
AI/Machine Learning for Early Drug Discovery – Part 1
AI-Driven Drug Design and Lead Optimization for Small Molecule and Peptide Therapeutics
In Silico Drug Discovery Workshop
This workshop aims to provide scientists with best practices and standards for rigor in the field of computational drug discovery to enable accurate and reproducible results. This workshop will also cover case studies for AI-driven drug discovery campaigns as well as an overview of new trends and gaps in the field.
Eighth International Conference on Drug Discovery and Lead Optimization
Dr. Sean Ekins will be presenting on “Drug Discovery Applications of Machine Learning In a Small Company”.
Cambridge Healthtech Institute’s 3rd Annual AI/ML-Enabled Drug Discovery - Part 2
Predicting Proteolysis-Targeting Chimeras' (PROTACs) ADME/Tox Properties
Dimensionality reduction and visualization techniques for explainable applicability domains in molecular structure-based machine learning models
ACS Fall Meeting - Dimensionality reduction and visualization techniques for explainable applicability domains in molecular structure-based machine learning models
Assessing and Navigating Biosecurity Concerns and Benefits of Artificial Intelligence Use in the Life Sciences - August Information Gathering Meeting
This is the first in-person meeting of the consensus study, Assessing and Navigating Biosecurity Concerns and Benefits of Artificial Intelligence Use in the Life Sciences. The open session of this information gathering meeting will include initial briefings containing information relevant to study issues. The committee will also meet in closed session for project planning and review of topics and speakers for remaining meetings.
The Dark Side of AI: Dual Use of AI-powered Drug Discovery
Dr. Sean Ekins will be speaking at the Cybersecurity and Infrastructure Security Agency (CISA) hosted “Chemical Security Seminars 2024” meeting on the Dark Side of AI: Dual Use of AI-powered Drug Discovery.
Panel: Partnering in the rare disease space - industry perspectives
Very pleased to announce I will be on an industry panel (with some much bigger companies) and pitching at the upcoming World Orphan Drug Congress in Boston April 23-25. I look forward to seeing you there!
AI/ML for Early Drug Discovery Conference
Sean Ekins will be presenting “In Silico ADME/Tox In the Generative AI Paradigm”
SOT 63rd Annual Meeting
Dr’s. Thomas Lane, Fabio Urbina and Sean Ekins will be attending and presenting posters and a talk.